Related Experiment Video
Updated: Oct 12, 2025

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Role of melatonin in TLR4-mediated inflammatory pathway in the MTPT-induced mouse model
Sendegul Yildirim1, Ayse Ozkan2, Gunes Aytac3
1Akdeniz University, Faculty of Medicine, Department of Histology and Embryology, Antalya, Turkey.
Abstract:
Neuroinflammation has an essential role in various neurodegenerative diseases including Parkinson's disease (PD). Microglial activation as a result of neuroinflammation exacerbates the pathological consequences of the disease. The toxic effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes alpha-synuclein (α-synuclein) accumulation, which leads to dopaminergic neuron death in the MPTP-induced mouse model. Toll-like receptor 4 (TLR4) stimulates release of cytokine through NF-kB by activating glial cells, thus resulting in the death of dopaminergic neurons. Melatonin has the ability to cross the blood-brain barrier and protect neurons through anti-inflammatory properties. We hypothesized that melatonin could suppress TLR4-mediated neuroinflammation, decrease cytokine release due to the inflammatory response, and reduce dopaminergic neuron loss in the MPTP-induced mouse model. In the MPTP-induced mouse model, we aimed to assess the neuroinflammatory responses caused by TLR4 activation as well as the effect of melatonin on these responses. Three-month-old male C57BL/6 mice were randomly divided into five groups; Control (Group-C), Sham (Group-S), Melatonin-treated (Group-M), MPTP-injected (Group-P), and MPTP + melatonin-injected (Group-P + M). MPTP toxin (20 mg/kg) was dissolved in saline and intraperitoneally (i.p.) injected to mice for two days with 12 h intervals. The total dose per mouse was 80 mg/kg. Melatonin was administered (20 mg/kg) intraperitoneally to Group-M and Group-P + M twice a day for five days. Eight days after starting the experiment, the motor activities of mice were evaluated by locomotor activity tests. The effects on dopamine neurons in the SNPc was determined by tyrosine hydroxylase (TH) immunohistochemistry. TLR4, α-synuclein, and p65 expression was evaluated by immunostaining as well. The amount of TNF-alpha in the total brain was evaluated by western blot analysis. In our results seen that locomotor activity was lower in Group-P compared to Group-C. However, melatonin administration was improved this impairment. MPTPcaused decrease in TH immuno-expression in dopaminergic neurons in Group-P. TLR4 (p < 0.001), α-synuclein (p < 0.001), and p65 (p < 0.01) immuno-expressions were also decreased in Group-P+M compared to Group-P (using MPTP). TNF-α expression was lower in Group-C, Group-S, Group-M, and Group-P+M, when compared to Group-P (p < 0.0001) due to the absence of inflammatory response. In conclusion, our study revealed that melatonin administration reduced α-synuclein aggregation and TLR4-mediated inflammatory response in the MPTP-induced mouse model.
Insights
Melatonin treatment reduced alpha-synuclein aggregation and toll-like receptor 4 (TLR4)-mediated inflammation in a mouse model of Parkinson's disease (PD). This neuroprotective effect improved motor activity and preserved dopaminergic neurons.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Neuroinflammation, particularly microglial activation, plays a critical role in neurodegenerative diseases like Parkinson's disease (PD).
- Toll-like receptor 4 (TLR4) activation in glial cells triggers inflammatory cytokine release via NF-kB, leading to dopaminergic neuron death.
- The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model is used to study PD pathogenesis, involving alpha-synuclein accumulation and dopaminergic neuron loss.
Purpose of the Study:
- To investigate the potential of melatonin to suppress TLR4-mediated neuroinflammation in the MPTP-induced mouse model of PD.
- To assess melatonin's effect on cytokine release, alpha-synuclein accumulation, and dopaminergic neuron survival.
- To evaluate the impact of melatonin on motor deficits in the MPTP-induced PD model.
Main Methods:
- MPTP toxin was administered to induce Parkinson's-like pathology in C57BL/6 mice.
- Melatonin was administered intraperitoneally to assess its therapeutic effects.
- Locomotor activity, tyrosine hydroxylase (TH) immunohistochemistry, TLR4, alpha-synuclein, p65, and TNF-alpha expression were evaluated.
Main Results:
- MPTP injection significantly impaired locomotor activity and reduced TH expression in dopaminergic neurons.
- Melatonin administration improved motor function and preserved dopaminergic neurons.
- Melatonin treatment significantly decreased the expression of TLR4, alpha-synuclein, p65, and TNF-alpha in MPTP-treated mice.
Conclusions:
- Melatonin effectively suppresses TLR4-mediated neuroinflammation and alpha-synuclein aggregation in the MPTP-induced mouse model.
- Melatonin demonstrates neuroprotective properties, mitigating dopaminergic neuron loss and improving motor deficits.
- Melatonin holds promise as a therapeutic agent for Parkinson's disease by targeting key inflammatory pathways.

